INSYS Therapeutics Inc. (INSY)

7.43
0.23 3.00
NASDAQ : Health Technology
Prev Close 7.66
Open 7.59
Day Low/High 7.41 / 7.71
52 Wk Low/High 4.10 / 14.00
Volume 293.30K
Avg Volume 631.30K
Exchange NASDAQ
Shares Outstanding 74.25M
Market Cap 573.91M
EPS -3.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Robbins Arroyo LLP: Insys Therapeutics, Inc. (INSY) Securities Class Action Survives Motion To Dismiss

Robbins Arroyo LLP: Insys Therapeutics, Inc. (INSY) Securities Class Action Survives Motion To Dismiss

Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Insys Therapeutics, Inc.

Insys Therapeutics Is a Pretend Cannabis Stock

Insys Therapeutics Is a Pretend Cannabis Stock

It is time for investors to start differentiating between the Good, the Bad and the Ugly in cannabis stocks.

Insys Therapeutics Breaks Below 200-Day Moving Average - Notable For INSY

Insys Therapeutics Breaks Below 200-Day Moving Average - Notable For INSY

In trading on Friday, shares of Insys Therapeutics Inc crossed below their 200 day moving average of $7.21, changing hands as low as $6.85 per share. Insys Therapeutics Inc shares are currently trading off about 5.9% on the day.

How to Invest in Cannabis - In Its Many Forms

How to Invest in Cannabis - In Its Many Forms

As cannabis becomes more and more legal, investors have started to wonder what that means for them.

What's the Difference Between Indica vs. Sativa?

What's the Difference Between Indica vs. Sativa?

Indica and sativa are commonly-known distinctions among cannabis enthusiasts. But is there actually a distinct difference between the two? What roles do cannabinoids and terpenes play?

FDA Approval Of GW Pharma's Cannabis-Based Drug Marks Milestone

FDA Approval Of GW Pharma's Cannabis-Based Drug Marks Milestone

Approval of epilepsy drug using the marijuana derivative CBD is the first time the FDA has sanctioned medical use of cannabidiol.

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

The milestone approval of Epidiolex bodes well for cannabis-based drug stocks GW Pharma, Nemus, Zynerba and Insys.

China Pledges Help With Fentanyl Imports; Says U.S. Must Curb Opioid Demand

China Pledges Help With Fentanyl Imports; Says U.S. Must Curb Opioid Demand

Despite a growing trade war between the U.S, and China, drug officials in that country have pledged to try to stop the flow of fentanyl into the U.S.

Johnson Fistel Announces Investigations Of Veevo Instruments Inc., Insys Therapeutics, Inc., TAL Education Group And Newell Brands Inc.; Investors Encouraged To Contact Firm

Johnson Fistel Announces Investigations Of Veevo Instruments Inc., Insys Therapeutics, Inc., TAL Education Group And Newell Brands Inc.; Investors Encouraged To Contact Firm

SAN DIEGO, June 23, 2018 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Veevo Instruments Inc.

Seven U.S. Stocks Offering Cannabis Exposure

Seven U.S. Stocks Offering Cannabis Exposure

While cannabis remains illegal on a federal level, these seven names are making early inroads into the growing industry.

First Week Of INSY July 20th Options Trading

Investors in Insys Therapeutics Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

First Week Of November 16th Options Trading For Insys Therapeutics (INSY)

First Week Of November 16th Options Trading For Insys Therapeutics (INSY)

Investors in Insys Therapeutics Inc saw new options become available this week, for the November 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Novartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med Pot

Novartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med Pot

Novartis subsidiary Sandoz Canada will work with cannabis producer Tilray to produce non-smokable medical cannabis products in Canada, becoming the first Big Pharma company to get into medical pot.

INSYS Therapeutics Reports Fourth Quarter And Full Year 2017 Results

INSYS Therapeutics Reports Fourth Quarter And Full Year 2017 Results

Foundation to become global leader in pharmaceutical cannabinoids and spray technology established in 2017 through new leadership and acceleration of product pipeline

Commit To Buy Insys Therapeutics At $5, Earn 26.7% Annualized Using Options

Commit To Buy Insys Therapeutics At $5, Earn 26.7% Annualized Using Options

Investors eyeing a purchase of Insys Therapeutics Inc stock, but tentative about paying the going market price of $7.57/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $5 strike, which has a bid at the time of this writing of 60 cents.

INSYS Therapeutics Initiates Phase 3 Clinical Trial Of Cannabidiol (CBD) Oral Solution For Treatment Of Infantile Spasms

INSYS Therapeutics Initiates Phase 3 Clinical Trial Of Cannabidiol (CBD) Oral Solution For Treatment Of Infantile Spasms

Pivotal study aims to evaluate safety and efficacy of company's novel CBD product candidate in rare type of pediatric epilepsy

First Week of April 20th Options Trading For Insys Therapeutics (INSY)

First Week of April 20th Options Trading For Insys Therapeutics (INSY)

Investors in Insys Therapeutics Inc saw new options begin trading this week, for the April 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new April 20th contracts and identified one put and one call contract of particular interest.

The Hottest Investing Plays in the Booming Weed Industry for 2018

The Hottest Investing Plays in the Booming Weed Industry for 2018

Marijuana stocks are still in their infancy, meaning there's a whole host of weed-adjacent stock moves waiting to be made. Here are the best bets.

Opioid Litigants Get Boost From Senate Report

Opioid Litigants Get Boost From Senate Report

A report released by Missouri Sen. Claire McCaskill points to $10 million of payments flowing from a group of five opioid-producing companies to 15 patient advocacy groups over a five-year period.

TheStreet Quant Rating: E+ (Sell)